Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments
Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...
bovnews5h
Vigil Neuroscience Inc (VIGL) Reported a – Operating Margin Last Year—What’s the Real Story?
William Blair has recently initiated Vigil Neuroscience Inc (VIGL) stock to Outperform rating, as announced on December 4, 2024, according to Finviz. Earlier, on December 19, 2023, Morgan Stanley had ...
The Pharma Letter6h
Vigil moves into Phase II with Alzheimer's pill
Vigil Neuroscience advances VG-3927, a small molecule TREM2 agonist, into Phase II Alzheimer’s trials in Q3 2025 following ...
BioPharma Dive25m
Mixed results for Keytruda; AbbVie to work with Neomorph
Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...
bovnews4h
Newegg Commerce Inc (NEGG) Posted – Profit Margin Last Year—Can It Hold Up?
In recent trading, Newegg Commerce Inc (NEGG) stock price has shown some volatility, fluctuating 12.47% over the last five trades and 8.08% over the past 30 trades. This represents a notable shift ...
US Health Agency CMS To Appeal Medicare Star Ratings Recalculation Ruling
The U.S. health agency, the Centers for Medicare & Medicaid Services (CMS), announced Tuesday that it will appeal a November 2024 ruling to the Fifth Circuit Court of Appeals. What Happened: In ...